Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TYK-00540 plus Enzalutamide in mCRPC
NCT07104643Phase 2Not yet recruiting
- Sponsor
- TYK Medicines
- Start
- Aug 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TYK-00540 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by TYK Medicines. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
TYK-00540
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07104643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07104643.